"Merck is threatening to exploit that invention," known as immunotherapy, with a later-developed method of treatment, in violation of a May 20 patent, Bristol-Myers said in a lawsuit filed yesterday in federal court in Wilmington, Delaware. The New York-based company is seeking unspecified damages.
“Merck is threatening to exploit that invention,” known as immunotherapy, with a later-developed method of treatment, in violation of a May 20 patent, Bristol-Myers said in a lawsuit filed yesterday in federal court in Wilmington, Delaware. The New York-based company is seeking unspecified damages.
Merck yesterday won US approval for Keytruda, an immunotherapy chemically known as pembrolizumab, to treat advanced melanoma, the deadliest version of skin cancer. Bristol-Myers and Merck have been in a race with
and
, who are also working on similar treatments, and the emerging class of drugs is seen as a new chapter in cancer therapy, with the potential to be applied to multiple forms of the disease.
Read the full story:
Roche Holding AG (ROG)Novartis AG (NOVN)
Source: Bloomberg
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Patient Navigation in Oncology at Heart of Priority Health White House Visit
April 24th 2024On March 27, Priority Health's president and CEO, Praveen Thadani participated in a discussion on how to expand and optimize patient navigation services in oncology care, as part of the Cancer Moonshot initiative.
Read More